Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors

NCT02700568 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Renal Cell
Clear Cell Renal Cell Carcinoma

Interventions

DRUG: axitinib

Sponsor

Kidney Cancer Research Bureau